No Data
Abeona Therapeutics Is Maintained at Overweight by Cantor Fitzgerald
Abeona Therapeutics Is Maintained at Overweight by Cantor Fitzgerald
Express News | Cantor Fitzgerald Maintains Overweight on Abeona Therapeutics, Lowers Price Target to $21
Abeona Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/16/2024 337.5% Cantor Fitzgerald $28 → $21 Maintains Overweight 04/23/2024 650% Cantor Fitzgerald → $36
Abeona Therapeutics Inc (ABEO) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances ...
Q1 2024 Abeona Therapeutics Inc Earnings Call
Express News | Abeona Therapeutics Shares Are Trading Higher. The Company Reported Q1 Financial Results